Eli Lilly CEO David Ricks put a number on a problem the pharmaceutical industry has been dancing around: even at peak adoption, the company’s blockbuster weight-loss drugs may reach only about half the Americans who could medically benefit from them. Ricks made the projection in April 2026, pointing to deep structural barriers in the U.S. healthcare system that no single drugmaker can dismantle alone. For a company whose obesity franchise, anchored by the injectable tirzepatide sold as Zepbound, generated billions in revenue last year, the admission is striking.
What Ricks actually said
According to Reuters, Ricks framed the roughly 50% ceiling not as a demand problem but as a delivery problem. Financial constraints and healthcare-system complexity, he said, would prevent GLP-1 medications from reaching everyone who qualifies. He did not release specific cost figures or insurer denial rates, but the barriers he described are well documented: coverage gaps, prior-authorization requirements, and out-of-pocket costs that can run into hundreds of dollars a month even for insured patients.
The population Ricks is measuring against is vast. Federal data from the CDC’s National Health and Nutrition Examination Survey (NHANES), which relies on direct physical measurements rather than self-reported weight, puts the adult obesity prevalence in the United States at roughly 42%. That translates to well over 100 million adults aged 20 and older. Add in those classified as overweight with obesity-related health conditions, and the clinically eligible pool grows larger still.
Reporting in the Wall Street Journal indicates Ricks wants to push that ceiling higher, not simply accept it. Lilly is investing in expanded manufacturing and in oral formulations, including the late-stage candidate orforglipron, that could lower production costs and eliminate the need for injections. But wanting broader access and achieving it are different things, and Ricks’ own 50% estimate suggests the company’s internal models see hard limits that ambition alone will not overcome.
Why the ceiling exists
The single largest structural barrier is Medicare. Federal law has historically prohibited Medicare Part D from covering drugs prescribed solely for weight loss. Legislation to change that exclusion has been introduced in Congress repeatedly but has stalled over cost concerns, given that Medicare covers tens of millions of older adults with high obesity rates. Until that statute changes, a huge segment of the population most likely to need these medications is effectively locked out of coverage.
Private insurance is uneven in its own way. Employer-sponsored plans vary widely in whether they cover GLP-1 drugs for obesity versus diabetes only. Lilly’s tirzepatide is approved both as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, but an insurer may cover one indication and deny the other. Prior-authorization rules add friction: patients and physicians must document failed attempts at diet and exercise, meet specific BMI thresholds, and sometimes reapply every few months. Each step creates a dropout point.
Medicaid, which covers lower-income Americans, operates state by state with its own formularies and restrictions. States with the highest obesity prevalence, concentrated in the South and Midwest, often face the tightest budgets. That creates a compounding problem: the populations with the greatest clinical need live in the jurisdictions least able to pay for treatment.
The CDC classifies obesity as a chronic disease linked to elevated risks of type 2 diabetes, cardiovascular disease, and certain cancers. Clinical trials of tirzepatide and rival GLP-1 drugs have shown not just significant weight loss but improvements in blood glucose, blood pressure, and other metabolic markers. The medical case for broad access is strong. The fiscal and administrative case remains contested.
The competitive picture
Lilly is not operating in a vacuum. Novo Nordisk, maker of the injectable semaglutide sold as Wegovy for obesity and as Ozempic for diabetes, is racing to expand its own manufacturing and develop next-generation compounds. Both companies have faced supply constraints that gave insurers a practical reason to keep utilization controls tight. If production catches up to demand and competition drives prices down, payers could loosen restrictions, potentially pushing penetration above Ricks’ 50% estimate.
Oral formulations represent the next front. Novo Nordisk’s oral semaglutide is already on the market for diabetes, and higher-dose versions aimed at obesity are in development. Lilly’s orforglipron, a non-peptide GLP-1 agonist taken as a daily pill, is in Phase 3 trials. Pills eliminate the need for injection training and cold-chain shipping, which could reduce distribution costs and make the drugs more accessible in primary-care settings where most obesity is managed. Whether those savings translate into lower prices for patients remains an open question.
What the 50% figure does and does not tell us
Ricks’ projection carries weight because of who he is. The CEO of one of the two dominant GLP-1 manufacturers has access to proprietary market models, payer negotiations, and clinical pipeline data that outside analysts do not. Corporate leaders rarely volunteer conservative market estimates without reason. His willingness to name a specific ceiling suggests Lilly sees constraints that marketing spend and manufacturing expansion cannot fully overcome.
That said, the figure has clear limitations. Ricks did not define “peak” with a timeline. Whether he means five years or fifteen years changes the calculus for patients, investors, and policymakers. His comments, as reported, were filtered through secondary coverage rather than a full public transcript, so the precise framing and caveats he may have offered are not fully visible.
The projection also does not distinguish between people who cannot get the drugs and people who choose not to take them. Some eligible patients will decline treatment over concerns about side effects, the commitment to long-term medication, or personal preference. Others will want the drugs and be blocked by cost or coverage. The policy response looks very different depending on which group accounts for more of the gap, and no publicly available data from Lilly or federal payer databases breaks that down.
Where access goes from here
Several forces could shift the ceiling in either direction over the next few years. Congressional action on Medicare coverage would be the single biggest lever. Expanded state Medicaid formularies, employer plan redesigns, and manufacturer discount programs could each chip away at the gap incrementally. On the other side, budget pressure, long-term safety questions that have not yet surfaced in trials, or slower-than-expected manufacturing scale-up could keep access flat or push it lower.
For now, Ricks’ 50% figure serves as a useful corrective to the hype cycle that has surrounded GLP-1 drugs since they burst into mainstream awareness. The science is real. The clinical benefits are well documented. But the American healthcare system was not built to deliver a single class of medication to 100 million people quickly or equitably. Until the structural barriers Ricks described are addressed one by one, the gap between who could benefit and who actually gets treated will remain one of the defining tensions in obesity care.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
